

Cannabinoid formulation benefits opioid-refractory pain

June 13 2012



A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of *The Journal of Pain*.

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of *The Journal of Pain*.

Russell K. Portenoy, M.D., of the Beth Israel Medical Center in [New York City](#), and associates conducted a randomized, double-blind, placebo-controlled, graded-dose study of 263 patients with advanced [cancer](#) and opioid-refractory pain. Participants were randomly allocated to receive low-, medium-, or high-dose nabiximols or placebo. During five-weeks of treatment, average pain, worst pain, and sleep [disruption](#) were measured daily; [quality of life](#) and mood were also assessed.

The researchers found that, compared with placebo, the 30 percent responder rate primary analysis was not significant for nabiximols ($P = 0.59$). In a secondary continuous responder analysis of average daily pain, a significantly higher proportion of patients reported analgesia in the nabiximols group than placebo ($P = 0.035$), specifically for low-dose and medium-dose nabiximols ($P = 0.008$ and 0.039 , respectively). Results were similar for mean average pain, mean worst pain, and mean sleep disruption in the low-dose group ($P = 0.006$, 0.011 , and 0.003 , respectively). There were no significant group differences seen in other [questionnaires](#). Dose-related adverse events were seen, with only the high-dose group comparing unfavorably with placebo.

"Based on the results of this dose-ranging study, nabiximols in a manageable dose range may prove to offer benefits to a very ill population with refractory pain," the authors write. "Confirmatory studies are strongly warranted."

The study was funded by GW Pharmaceuticals, which produces nabiximols, and Otsuka.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2012 [HealthDay](#). All rights reserved.

Citation: Cannabinoid formulation benefits opioid-refractory pain (2012, June 13) retrieved 18 April 2024 from
<https://medicalxpress.com/news/2012-06-cannabinoid-benefits-opioid-refractory-pain.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--